SW480-luc Orthotopic Mouse Model Service for Colon Cancer

The SW480-luc orthotopic mouse model pairs a luciferase-reporter human colorectal adenocarcinoma line carrying the canonical KRAS G12V driver mutation with anatomically faithful cecal wall implantation, enabling serial, non-invasive visualization of tumor establishment, local growth, and therapeutic response within a Dukes' B-stage microenvironment. Alfa Cytology assembles and manages this model with authenticated SW480-luc cell assets, refined surgical protocols, and integrated IVIS bioluminescence imaging infrastructure, supplying researchers with a quantitative platform for evaluating KRAS-targeted therapeutics, Wnt pathway modulators, and combination regimens against MSS colorectal carcinoma.

Overview of SW480-luc Orthotopic Mouse Model for Colon Cancer

The SW480-luc cell line is a luciferase-transduced derivative of the parental SW480 human colorectal adenocarcinoma line, originally established in 1976 by A. Leibovitz from a Dukes' stage B primary tumor resected from a 50-year-old Caucasian male. The parental line harbors a homozygous KRAS p.G12V activating mutation that drives constitutive MAPK signaling, a truncating APC mutation (p.Q1338Ter) that sustains canonical Wnt/β-catenin pathway activation, and compound TP53 missense alterations (p.R273H and p.P309S). Genomically classified as microsatellite stable (MSS) and CIMP-negative with a hypertriploid karyotype, SW480-luc retains the full parental mutational repertoire while constitutively expressing firefly luciferase (luc2) under the human EF1α promoter, permitting quantitative photon flux readouts that correlate with viable tumor biomass in vivo.

Fig 1. Workflow for establishing an SW480 GFP-Luc orthotopic colorectal cancer model, from reporter-labeled cell preparation to intestinal implantation and longitudinal analysis of primary tumor growth and metastatic progression. (Richon, Sophie, et al., 2023)

Orthotopic engraftment of SW480-luc cells into the murine cecal wall recapitulates the glandular architecture, stromal compartment, and invasive front dynamics of human Dukes' B colorectal adenocarcinoma. This anatomical placement preserves the luminal microbiome interface, submucosal vascular plexus, and mesenteric lymphatic drainage, thereby supporting locoregional progression and occasional distant dissemination. The built-in luciferase reporter enables non-invasive, longitudinal quantification of tumor dynamics without repeated surgical intervention, making this model particularly advantageous for kinetic pharmacodynamic studies, early efficacy screening, and real-time assessment of therapeutic response to KRAS-directed agents, Wnt pathway inhibitors, and 5-fluorouracil-based regimens in a translationally relevant MSS context.

Cell Line Information: SW480-luc

The table below presents a comprehensive compilation of the biological, genetic, and technical specifications of the SW480-luc human colorectal adenocarcinoma cell line, serving as a detailed reference for investigators designing preclinical studies in both in vitro and in vivo contexts.

Our Services

Alfa Cytology furnishes a full-spectrum SW480-luc orthotopic mouse model service calibrated for KRAS-mutant, MSS colorectal cancer preclinical research. Our scope encompasses authenticated SW480-luc master cell bank sourcing, mycoplasma clearance, and expansion under monitored passage limits, followed by precision cecal wall surgical implantation in immunocompromised hosts. Longitudinal tumor surveillance is conducted via scheduled IVIS bioluminescence imaging with calibrated photon flux quantification, while endpoint analyses span tumor biometrics, histopathology, immunohistochemistry, and molecular profiling of KRAS/MAPK and Wnt/β-catenin pathway markers. Each protocol element—from luciferase validation assays to imaging cadence and tissue triage—is tailored to your compound mechanism and translational objectives, yielding datasets suitable for peer-reviewed publication and regulatory dossier compilation.

Workflow of SW480-luc Orthotopic Mouse Model Construction

Construction of the SW480-luc orthotopic colon cancer model demands exacting surgical technique, stringent cell line stewardship, and standardized bioluminescence imaging protocols to achieve consistent engraftment and quantifiable therapeutic readouts. The operational framework described below is executed within specific pathogen-free barrier facilities, advancing through the following sequential stages:

1. Cell Line Authentication and Luciferase Validation: SW480-luc cells are revived from authenticated cryopreserved master stocks and expanded in Leibovitz's L-15 medium supplemented with 10% FBS. Prior to surgical deployment, cells undergo mandatory STR identity confirmation, mycoplasma PCR screening, and in vitro luciferase activity quantification via D-luciferin substrate assay to verify reporter expression stability and signal linearity across the anticipated cell density range.
2. Host Selection and Preoperative Conditioning: Female or male athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice aged 6–8 weeks are selected based on study design requirements. Animals are housed in specific pathogen-free vivaria under controlled temperature (22 ± 2°C), humidity (50 ± 10%), and a 12-hour light/dark cycle, with ad libitum access to irradiated chow and acidified water. A minimum five-day acclimation period is observed, during which baseline body weights and clinical observations are documented.
3. Anesthesia and Aseptic Surgical Field Establishment: On the day of implantation, mice are anesthetized with 2–3% isoflurane inhalation delivered via nose cone, with anesthetic depth confirmed by absence of pedal withdrawal reflex. The ventral abdominal wall is shaved and sterilized with sequential povidone-iodine and 70% ethanol applications. Sterile surgical drapes are positioned to maintain an aseptic operative field, and ophthalmic ointment is applied to prevent corneal desiccation.
4. Cecal Exposure and Orthotopic Cell Deposition: A 1.0–1.5 cm midline laparotomy is performed to access the peritoneal cavity. The cecum is gently exteriorized using atraumatic forceps and kept hydrated with warm sterile PBS. A single-cell suspension of 1 × 10⁶ to 2 × 10⁶ viable SW480-luc cells, resuspended in 25–50 µL of serum-free L-15 medium mixed 1:1 with growth factor-reduced Matrigel, is loaded into a 1 mL syringe fitted with a 30 G needle. The needle is inserted into the subserosal plane of the cecal wall at the anti-mesenteric border, and the cell suspension is slowly deposited to form a discrete submucosal bleb without mucosal perforation.
5. Hemostasis, Cecal Repositioning, and Abdominal Closure: The injection site is compressed gently with a sterile cotton swab for approximately 3 minutes to ensure hemostasis and prevent cell leakage into the peritoneal cavity. The cecal wall is inspected for integrity, then gently returned to anatomical position within the abdomen. The abdominal musculature is closed with absorbable 5-0 sutures in a continuous pattern, and the skin is apposed with surgical staples or tissue adhesive. Mice are transferred to a warmed recovery chamber and monitored until full ambulatory recovery.
6. Bioluminescence Imaging and Tumor Kinetics Surveillance: Beginning approximately 7–10 days post-implantation, tumor establishment is monitored via non-invasive bioluminescence imaging. Mice receive an intraperitoneal injection of D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Photon flux (photons/sec) is quantified within a standardized region of interest, with imaging frequency adjusted to study design—typically twice weekly during the growth phase and weekly during treatment phases. Conventional cohorts are additionally monitored by abdominal palpation and digital caliper measurement of externally palpable masses.
7. Stratified Randomization and Therapeutic Intervention: Once tumors achieve a predetermined bioluminescence signal intensity—typically 10⁶ to 10⁷ photons/sec—mice are stratified by tumor burden and body weight into treatment and vehicle control cohorts. Investigational agents are administered according to predefined dosing regimens, with routes selected based on pharmacokinetic properties and mechanism of action. Concurrent bioluminescence imaging continues to capture real-time therapeutic response kinetics.
8. Necropsy, Triage, and Multi-Platform Endpoint Analysis: At study termination, mice are humanely euthanized under deep anesthesia. The cecum and primary tumor are excised en bloc, photographed, and weighed. Tumor tissue is triaged for formalin fixation and paraffin embedding (H&E, IHC for Ki-67, CD31, phospho-ERK, β-catenin, axin2, cleaved caspase-3), snap-freezing for Western blot or RNA-seq, and dissociation for flow cytometric analysis. Ex vivo bioluminescence imaging of excised organs confirms metastatic dissemination to mesenteric lymph nodes, liver, lung, and peritoneum, with histological confirmation of all macroscopic lesions.

Fig 2. SW480-luc orthotopic mouse model construction workflow.

Case Study-SW480-luc Orthotopic Mouse Model Development

In a recent preclinical program, the SW480-luc orthotopic model was deployed to evaluate the anti-tumor efficacy of a covalent KRAS G12V-selective inhibitor administered in combination with a tankyrase antagonist that destabilizes axin and suppresses Wnt/β-catenin signaling. Following cecal wall implantation, tumor-bearing mice were stratified by bioluminescence signal and randomized into combination, KRAS inhibitor monotherapy, tankyrase inhibitor monotherapy, and vehicle control arms. Longitudinal in vivo imaging revealed progressive suppression of tumor photon flux in the combination cohort beginning at day 10 post-treatment initiation, whereas monotherapy arms showed only transient stabilization followed by rebound. Terminal histopathological analysis demonstrated markedly reduced nuclear β-catenin accumulation and attenuated phospho-ERK immunoreactivity in combination-treated tumors, alongside increased apoptotic fractions and diminished Ki-67 proliferation indices. These findings illustrate the translational utility of the SW480-luc orthotopic platform for discriminating combination synergy from single-agent activity and for generating mechanistic insights into co-targeting the KRAS/MAPK and Wnt/β-catenin axes in MSS colorectal adenocarcinoma.

Why Choose Alfa Cytology?

Selecting Alfa Cytology for your SW480-luc orthotopic model program ensures access to a technically refined service ecosystem engineered for quantitative, imaging-guided preclinical colorectal cancer research. Our operational differentiators include:

• Authenticated SW480-luc master cell banks with documented STR profiles, mycoplasma negativity, and sustained EF1α-driven luciferase expression stability across extended passage ranges.
• Standardized in vitro luciferase linearity assays ensuring quantitative signal-to-cell-number correlation prior to in vivo deployment, safeguarding imaging fidelity throughout the study duration.
• Experienced microsurgical teams proficient in cecal wall orthotopic implantation, achieving high tumor take rates with minimal perioperative complications and rapid postoperative recovery.
• On-site IVIS bioluminescence imaging infrastructure enabling scheduled longitudinal tumor monitoring with calibrated photon flux quantification and automated region-of-interest analysis.
• Comprehensive endpoint triage protocols encompassing KRAS/MAPK and Wnt/β-catenin pathway marker profiling (phospho-ERK, β-catenin, axin2), alongside standard histopathological and molecular analyses.
• Flexible study architectures accommodating monotherapy, combination, and sequential dosing paradigms, with stratified randomization based on real-time bioluminescence tumor burden metrics.

Contact Us

Whether your preclinical pipeline requires a rigorously validated SW480-luc orthotopic model for evaluating KRAS G12V-directed therapeutics, Wnt pathway modulators, or combination regimens against MSS colorectal cancer, the scientific team at Alfa Cytology is prepared to design a customized study framework aligned with your therapeutic targets and translational milestones. Contact us today to discuss your project parameters, request a detailed service quotation, or schedule a technical consultation with our colorectal cancer model specialists.

For research use only. Not intended for any clinical use.